Apatinib, a new gastric cancer drug of Hengrui medicine, has obtained new drug certificate
-
Last Update: 2014-11-04
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to reports, apatinib is mainly used in the treatment of advanced gastric cancer after the failure of standard chemotherapy It is the first small molecule anti angiogenesis targeted drug proved safe and effective in the world, and also the only oral drug delivery agent in the targeted treatment of gastric cancer Apatinib lasted for 10 years from the initiation of research and development to its approval for marketing It is a major new drug creation project in the 11th Five Year Plan and 12th Five Year Plan of China Hengrui pharmaceutical said it would start to arrange production as soon as possible, and focus on increasing market promotion, so as to make apatinib play its role as soon as possible, bring benefits to patients and create greater value for shareholders.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
